UnitedHealth Group Incorporated Revenue & Financials

UnitedHealth Group's financial profile is defined by an unusual combination: enormous revenue scale generated by insurance premium flows, paired with structurally narrow insurance margins that are substantially enriched by Optum's higher-margin health services businesses. Understanding the consolidated financial picture requires examining segment-level economics rather than treating the aggregate income statement as a monolithic unit. For fiscal year 2024, UnitedHealth Group reported total revenues of $400.3 billion, a 7.8% increase over fiscal year 2023's $371.6 billion and a continuation of the company's decade-long pattern of compounding revenue growth. The UnitedHealthcare segment contributed approximately $281 billion in premium and fee revenues, while Optum generated approximately $236 billion in revenues including significant intercompany transactions with UnitedHealthcare. Intercompany eliminations, which remove revenues recorded by both segments for services exchanged within the enterprise, reduce the consolidated total to $400.3 billion and represent a concrete financial expression of the vertical integration strategy. Total operating income before Change Healthcare-related costs was approximately $18.9 billion for fiscal year 2024. However, the $3.1 billion in direct Change Healthcare cyberattack costs — remediation expenses, provider advance payments, temporary infrastructure, and settlement-related reserves — reduced reported operating income substantially. Adjusted net earnings attributable to UnitedHealth Group common shareholders were approximately $14.4 billion. The company's effective tax rate of approximately 21% reflected a combination of statutory federal rates and state tax obligations across its diversified geographic operations. The medical loss ratio for the UnitedHealthcare segment rose above historical levels during 2024, reaching approximately 85.2% for the full year compared to approximately 82.8% in 2022. The MLR elevation reflected higher-than-anticipated Medicare Advantage medical costs — particularly for outpatient services, GLP-1 pharmaceutical spending, and post-acute care utilization — that the company's actuarial models had not fully anticipated. This MLR pressure was the primary driver of the earnings revisions and stock price decline that occurred through 2024. Optum's margin profile meaningfully exceeded the insurance segment. OptumRx, as a PBM and specialty pharmacy operator, generated operating margins in the mid-to-high single digits on its enormous transaction volumes. Optum Health's care delivery business, operating increasingly on value-based risk contracts, generated higher margins on attributed Medicare populations where care management effectiveness drove medical cost savings. Optum Insight's software and data analytics products generated the highest operating margins within the enterprise, in line with health IT software industry benchmarks, though these were partially offset by remediation costs following the Change Healthcare attack. Free cash flow generation, historically one of the company's strongest financial metrics, produced approximately $21-22 billion in cash from operations in fiscal year 2024. The insurance business model's working capital dynamics — premiums collected in advance of claims payment — support cash conversion ratios that often exceed reported net income, providing substantial capital for dividend payments, share repurchases, debt service, and selective acquisitions. The company has been a consistent dividend grower, maintaining its pattern of annual dividend increases that reflects management's confidence in the long-term earnings trajectory even during periods of operational disruption. Long-term debt of approximately $47 billion as of year-end 2024 reflects the cumulative capital deployed in major acquisitions over the preceding decade.